argenex SE $ARGX Stock: Jefferies Financial Group Inc. Increases Holdings

Jefferies Financial Group Inc. raised its position in argenex SE (NASDAQ:ARGX) by 55.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 70,000 shares of the company’s stock after buying an additional 24,932 shares during the quarter. argenex comprises about 0.5% of Jefferies Financial Group Inc.’s portfolio, making the stock its 19th largest position. Jefferies Financial Group Inc. owned about 0.11% of argenex worth $67,124,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Tidal Investments LLC boosted its position in shares of argenex by 97.8% during the 2nd quarter. Tidal Investments LLC now owns 2,362 shares of the company’s stock worth $2,191,000 after acquiring an additional 1,168 shares in the last quarter. Squarepoint Ops LLC raised its position in argenex by 314.8% during the second quarter. Squarepoint Ops LLC now owns 58,400 shares of the company’s stock valued at $54,182,000 after purchasing an additional 44,321 shares in the last quarter. Peregrine Capital Management LLC acquired a new position in argenex during the second quarter valued at approximately $27,584,000. Assenagon Asset Management S.A. raised its position in argenex by 120.3% during the third quarter. Assenagon Asset Management S.A. now owns 36,417 shares of the company’s stock valued at $34,921,000 after purchasing an additional 19,886 shares in the last quarter. Finally, Optiver Holding B.V. lifted its stake in argenex by 907.0% during the first quarter. Optiver Holding B.V. now owns 10,110 shares of the company’s stock worth $7,383,000 after purchasing an additional 9,106 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ARGX shares. Sanford C. Bernstein reaffirmed a “buy” rating on shares of argenex in a report on Thursday, October 8th. Deutsche Bank reissued a “neutral” rating on shares of argenex in a report on Friday, October 9th. Truist Financial upped their price objective on argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Wells Fargo & Company dropped their price objective on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating for the company in a research report on Friday, October 23rd. Finally, Oppenheimer reduced their price objective on argenex from $1,100.00 to $1,038.00 and set an “outperform” rating on the stock in a research note on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,158.76.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $977.58 on Thursday. The company has a market cap of $61.48 billion, a price-to-earnings ratio of 34.11, a PEG ratio of 0.90 and a beta of 0.48. The firm has a 50 day simple moving average of $927.22 and a 200 day simple moving average of $859.56. argenex SE has a one year low of $661.85 and a one year high of $1,072.75.

argenex (NASDAQ:ARGX) last posted its earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a net margin of 31.66% and a return on equity of 47.70%. As a group, analysts expect that argenex SE will post 28.41 EPS for the current year.

About argenex

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.